Matt Phipps

if you could give us any details on how you might design future studies, especially around the use of a low-dose active control

I wonder if that changes your view at all on the business, maybe some of the barriers to entry, but also the calculus on what biologics might be worth pursuing a biosimilar for?

Just curious how that program differentiates from TEPEZZA and maybe what unmet need you're looking to address in thyroid eye disease?

I actually wanted to ask about the market opportunity for TEZSPIRE and CRS nasal polyps in a mitigation that gets talked a lot about.

how meaningful is this market opportunity expansion

any particular indications or physician settings where you're seeing more adoption or more interest in Keviantic

is there a time course that the FDA wants as far as how much durability on that MRD

is there a point at which Abema what is kind of the profitability breakpoint for Abema

I just wanted to confirm that all studies have resumed enrollment following that temporary pause a month or so ago

did the pre-NDA discussions with the FDA discuss the potential to include biologic-naive patients in the labeled indication

can you maybe just remind us on the learnings from the robust trial that were incorporated into front line, where you think you can succeed

if you still see that as a risk at some point this year? Or if you think you're at a good point with payer contracting that, that's not a concern?

is there any correlation with eosinophil levels?

Do you have any sense yet on what dose is getting preference for prescription of BRINSUPRI?